Tun da akwai nau'i daban -daban na masu ƙyama da aka yi amfani dasu don magance COPD , yawancin marasa lafiya zasu iya yin tunani "wane ne mafi kyau?" Yayin da yake yarda cewa yana da haɗari don ganewa cewa akwai 'likita mafi kyau' don kowane yanayin, a cikin yanayin COPD, daya daga cikin magungunan sunyi kama da wasu, wanda ya sami wannan lakabin "wakilin farko" don magance COPD.
Aikin magani ana kiransa masu haɗari masu tayar da hankali, wanda a halin yanzu akwai a kasuwannin: Spiriva (tiotropium) da Turdoza (aclidinium bromide). Tun lokacin da Turdoza ya zo kasuwa a shekarar 2012, yawancin gwajin gwaji da suka shafi marasa lafiya COPD sunyi amfani da maganin Spiriva (wanda ya zo a kasuwa a shekara ta 2004). Saboda haka, a cikin wannan labarin, zamu yi magana game da Spiriva ta hanyar taƙaita muhimman binciken binciken biyu masu muhimmanci game da Tiotropium, wanda ke goyan bayan matsayinsa "na farko na mai sukarwa ga marasa lafiya na COPD." Sa'an nan, zamuyi magana game da sakamakon Spiriva.
Kwatanta Spiriva
A cikin Maris 24, 2011 na New England Journal of Medicine (daya daga cikin mujallu na farko na kiwon lafiya), wata ƙungiyar masu bincike sun yi fatan za su gano ko wane ɗayan maganin likita ne mafi alhẽri a hana ƙwaƙwalwar COPD: magungunan magunguna ko masu tsaurin ra'ayi. Don yin haka, sun kwatanta Tiotropium (Spiriva, anticholinergic) tare da Salmeterol (Serevent, mai maganin beta) a cikin marasa lafiya da COPD mai tsanani.
Sun auna tsawon lokacin da marasa lafiya suka fuskanci kwarewa na farko na COPD. Sun gano cewa marasa lafiya da suka yi amfani da Spiriva suna da kashi 17 cikin 100 na hadarin da ake ciki na COPD da kuma kashi 28 cikin 100 na hadarin ya zama mummunar wahala. Magunguna da suka yi amfani da Spiriva suna da kwanaki 187 har sai da farko da suka yi nisa a inda marasa lafiya da suka yi amfani da Serevent suna da kwanaki 145 zuwa farkon gwagwarmaya.
Bugu da ƙari, marasa lafiya da suka dauki Spiriva suna da ƙananan bukata don steroid (irin su prednisone) da maganin rigakafi. Babu bambance-bambance a cikin nau'i ko nau'i na sakamako masu illa daga magunguna.
Wani binciken a New England Journal of Medicine (daga 2008) ya sami wani gwajin inda suka bi marasa lafiya 3000 suka dauki Spiriva kuma suka kwatanta su da marasa lafiya 3000 waɗanda suka yi amfani da 'sham' inhaler. Dukkan kungiyoyin marasa lafiya sun yarda suyi amfani da wasu magunguna a yayin binciken. Wadanda suka yi amfani da Spiriva, duk da haka, suna da ƙwayar cuta, ƙananan asibiti, rashin rashin lafiya na numfashi, da kuma mafi kyau a cikin binciken kwayar cutar fiye da marasa lafiya da basu yi amfani da Spiriva ba. Wannan binciken ya jagoranci masu bincike su tabbatar da cewa Spiriva zai iya inganta alamun bayyanar cutar, rage yawan haɓaka da kuma inganta yanayin rayuwa ga marasa lafiya tare da COPD (idan aka kwatanta da waɗanda basu yi amfani da Spiriva ba).
Kodayake Spiriva shine yawancin zabi na farko ga mai kwantar da hankali, akwai wasu masu haɗari waɗanda aka nuna a COPD, irin su Advair, Symbicort, da sauransu. Mutane da yawa marasa lafiya suna buƙatar fiye da daya inhaler, kuma ga wasu marasa lafiya, Spiriva ba BA mafi kyau zabi (misali, idan sun fuskanci sakamako masu illa). Har ila yau akwai wasu masu haɗaka waɗanda basu dace da Spiriva ba (alal misali, kada ku yi amfani da Spiriva da Combivent tare )
Sakamakon sakamako na Spiriva suna da ban sha'awa, kuma yana iya haɗawa da:
Tsuntsar mahaifa (musamman a cikin maza da kara karuwanci)
Maganin haushi (amya, itching, rash, kumburi lebe / harshen / makogwaro)
Glaucoma (ciwon ido, hangen nesa, ganin halos ko launuka mara kyau)
Ƙari mafi rinjaye na Spiriva sun haɗa da:
Dry baki
Sashin sinus
Sore baƙin ciki
Binciken Blurry
Babban zuciya
Ƙananan cututtuka na fili na numfashi
Ga wani ban sha'awa mai kayatarwa game da Hannun Spiriva (wanda aka buga a New England Journal of Medicine ), danna nan.
Sources
> Tashkin DP, Celli B, Senn S, et al. Yunkurin shekaru 4 na tiotropium a cikin cututtuka na ciwon huhu na yau da kullum. N Engl J Med 2008; 359: 1543-54.
> Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol don kare rigakafin COPD. N Engl J Med 2011; 364: 1093-103.
> Mai hikima RA, Anzueto A, Cotton D, et al. Tiotropium Sake yin amfani da shi da kuma hadarin mutuwar a COPD. N Engl J Med 2013; 369: 1491-501.